Kelly Stratton, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (General Urology)
    Ineligible company: 
    MERK & Company Inc.
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    03/22/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Sanofi Genzyme Corp.
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    03/22/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (General Urology)
    Ineligible company: 
    Bayer Corporation
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    03/22/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (General Urology)
    Ineligible company: 
    MJH Life Sciences
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    03/22/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    AstraZeneca
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    03/22/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Janssen Pharmaceuticals
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    03/22/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    MJH Life Sciences
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    03/22/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Oakstone
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    03/22/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Ebix
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    03/22/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Merck & Company, Inc.
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    03/22/2023

Pages

Return to The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion (2023)